Vivos Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Vivos Therapeutics (VVOS) with a Buy rating and $7 price target Vivos is a commercial-stage medical device company focused on the commercialization of non-surgical treatment of maxillofacial abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders, the analyst tells investors in a research note. The firm expects the company’s new business model and initiatives to drive solid sales growth in the coming years.